跳至主要内容
临床试验/NL-OMON31048
NL-OMON31048尚未招募不适用

Molecular imaging with radiolabeled bevacizumab in metastatic colon carcinoma; a feasibility study in patients who do not show response on bevacizumab therapy. - Radiolabeled bevacizumab in resistant patients with colon carcinoma

niversitair Medisch Centrum Groningen0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Metastatic colon cancer.
  • 2. Progression of disease (RECIST) after chemotherapy including bevacizumab
  • 3. At least 18 years of age.
  • 4. A life expectancy of at least 3 months.
  • 5. Adequate hematologic, hepatic, and renal function.
  • 6. Signed written informed consent.
  • 7. Able to comply with the protocol.

排除标准

  • 1.Radiotherapy within 14 days before the start of the study of the involved area.
  • 2.Major surgery within 28 days before the initiation of the study.
  • 3.Clinically significant cardiovascular disease.
  • 4.Pregnant or lactating women. Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause.
  • 5.CNS metastases (CT-scan not mandatory).
  • 6.Treatment with any investigational drug within 30 days before the start of the study.
  • 7.Prior allergic reaction to immunoglobulins or immunoglobulin allergy.

研究者

相似试验